Regeneron Pharmaceuticals, Inc. financial data

Symbol
REGN on Nasdaq
Industry
Pharmaceutical Preparations
Location
777 Old Saw Mill River Road, Tarrytown, NY
State of incorporation
NY
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 517 % -4.99%
Quick Ratio 79.6 % +4.48%
Debt-to-equity 27.9 % -0.39%
Return On Equity 15.5 % -3.55%
Return On Assets 12.1 % -3.51%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 114B USD +48.4%
Weighted Average Number of Shares Outstanding, Basic 108M shares +1.13%
Weighted Average Number of Shares Outstanding, Diluted 115M shares +1.23%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 14.2B USD +8.27%
Research and Development Expense 5.13B USD +15.6%
Costs and Expenses 10.2B USD +12.6%
Operating Income (Loss) 3.99B USD -1.39%
Nonoperating Income (Expense) 789M USD +419%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 4.78B USD +13.8%
Income Tax Expense (Benefit) 367M USD +49.5%
Net Income (Loss) Attributable to Parent 4.41B USD +11.6%
Earnings Per Share, Basic 40.9 USD/shares +10.4%
Earnings Per Share, Diluted 38.3 USD/shares +10.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.49B USD -8.86%
Marketable Securities, Current 6.52B USD -19.6%
Accounts Receivable, after Allowance for Credit Loss, Current 6.21B USD +9.61%
Inventory, Net 3.09B USD +19.6%
Assets, Current 18.7B USD -4.2%
Deferred Income Tax Assets, Net 3.31B USD +28.7%
Operating Lease, Right-of-Use Asset 217M USD +179%
Intangible Assets, Net (Excluding Goodwill) 1.15B USD +10.6%
Other Assets, Noncurrent 1.14B USD +156%
Assets 37.8B USD +14.1%
Accounts Payable, Current 790M USD +30.2%
Employee-related Liabilities, Current 641M USD +3.67%
Contract with Customer, Liability, Current 628M USD +36.8%
Liabilities, Current 3.94B USD +15.2%
Contract with Customer, Liability, Noncurrent 186M USD +46.6%
Operating Lease, Liability, Noncurrent 204M USD +197%
Other Liabilities, Noncurrent 1.57B USD +84%
Liabilities 8.41B USD +18.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -7.9M USD +90.2%
Retained Earnings (Accumulated Deficit) 31.7B USD +16.2%
Stockholders' Equity Attributable to Parent 29.4B USD +13%
Liabilities and Equity 37.8B USD +14.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 1.51B USD +10.6%
Net Cash Provided by (Used in) Financing Activities 47.1M USD
Net Cash Provided by (Used in) Investing Activities -1.69B USD -616%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -128M USD -116%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.49B USD -9.09%
Deferred Tax Assets, Gross 3.41B USD +29.8%
Operating Lease, Liability 234M USD +167%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 4.49B USD +9.1%
Lessee, Operating Lease, Liability, to be Paid 291M USD +182%
Operating Lease, Liability, Current 30.3M USD +59.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 44.8M USD +123%
Lessee, Operating Lease, Liability, to be Paid, Year One 43.1M USD +78.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 56.5M USD +262%
Lessee, Operating Lease, Liability, to be Paid, Year Three 42.6M USD +173%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares 0%
Unrecognized Tax Benefits 1.31B USD +88.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 33.2M USD +168%
Additional Paid in Capital 12.9B USD +13.2%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 114M USD +14.7%
Interest Expense 71.1M USD +11.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%